EUCTR2008-002844-40-NL进行中（未招募）不适用
A DOUBLE BLIND, SINGLE DOSE, RANDOMIZED, 4-PERIOD CROSS-OVER, PLACEBO-CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE (CHF 1535) VERSUS SINGLE AGENTS FORMOTEROL FUMARATE AND BECLOMETHASONE DIPROPIONATE VIA pMDI WITH HFA-134A PROPELLANT, WHEN GIVEN AFTER INHALED ALLERGEN CHALLENGE IN ASTHMATIC PATIENTS - MART3
eiden University Medical Center0 个研究点目标入组 20 人开始时间: 2008年12月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Written informed consent;
- •-Male and female outpatients, aged ? 18 years and ? 55 years;
- •-Clinical diagnosis of controlled asthma for at least 6 months, according to Global Strategy for Asthma Management and Prevention (GINA) revised version 2007 guidelines, without severe exacerbation in the previous 6 months;
- •-Patients on short-acting ?2-agonists on needed, as the only asthma therapy;
- •-A provocative concentration (PC) of methacholine chloride or histamine causing a 20% fall in FEV1 (PC20) < 16 mg/ml;
- •-A positive skin prick test (SPT) for house dust mite (HDM);
- •-An EAR (? 20% fall in FEV1 from baseline, 0-3 h post allergen) and a LAR (? 15% fall in FEV1 from baseline, 3-8 h post-allergen) following inhaled allergen extract at screening;
- •-A co-operative attitude and ability to correctly use the device.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Current smokers or recent (less than one year) ex-smokers with a smoking history less than 10 pack years;
- •-Clinically significant history of upper/lower respiratory tract infection within 4 weeks from the start of the study;
- •-Clinically significant or unstable concurrent disease: e.g. uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; significant other pulmonary disease; cardiovascular disease; gastrointestinal disease; neurological disease; haematological disease, autoimmune disorders, laboratory and electrocardiographyc abnormalities that may interfere with patient’s safety, compliance, or study evaluations, according to the investigator’s opinion;
- •-Pregnant or lactating women. Females of childbearing potential with active desire to be pregnant or without an efficient contraception method. A negative pregnancy test in urine is to be verified in women of a fertile age at screening;
- •-Patients treated with long-acting ?2-agonists, anticholinergics and antihistamines in the previous week;
- •-Patients treated with leukotriene antagonists during the previous 2 weeks;
- •-Patients treated with inhaled or nasal corticosteroids in the previous 4 weeks;
- •-Patients treated for immunotherapy;
- •-Patients treated with anti-IgE antibodies in the previous 6 months;
- •-Patients treated with beta-blockers in the week preceding the screening visit;
- •-Patients who received systemic steroids in the last month;
- •-Significant alcohol consumption or drug abuse;
- •-Patients with allergy, sensitivity or intolerance to sympathomimetic drugs or corticosteroids or to any of the excipients contained in the study drugs;
- •-Inability to perform spirometry of acceptable quality (according to ERS guidelines) or any other acute or chronic condition that put the patient at risk or may alter the interpretation of the test;
- •-Patients who received any investigational new drug or participated in clinical study within the previous 8 weeks before study entry.
研究者
相似试验
已完成
4 期
A DOUBLE BLIND, SINGLE DOSE, RANDOMIZED, 4-PERIOD CROSS-OVER, PLACEBO-CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE (CHF 1535) VERSUS SINGLE AGENTS FORMOTEROL FUMARATE AND BECLOMETHASONE DIPROPIONATE VIA pMDI WITH HFA-134A PROPELLANT, WHEN GIVEN AFTER INHALED ALLERGEN CHALLENGE IN ASTHMATIC PATIENTSallergic asthmaobstructive lung desease10006436NL-OMON32042eids Universitair Medisch Centrum20
尚未招募
不适用
A comparative Bioavailability study of CCL in Healthy VolunteersCTRI/2020/07/026856Akay Natural Ingredients Pvt Ltd
已完成
1 期
Comparative bioequivalence study of a generic formulation of fingolimod capsule against the innovator fingolimod capsule in fasting healthy subjectsACTRN12615001055594Zenith Technology Corporation Limited24
已完成
不适用
Bioequivalence study for Rifapentine 150 mg TabletsCTRI/2022/04/042197Cipla Ltd India40
进行中（未招募）
不适用
A SINGLE-DOSE, RANDOMIZED, TWO-PERIOD, CROSSOVER STUDY TO ASSESS BIOEQUIVALENCE BETWEEN TWO IBUPROFEN 200 MG TABLET FORMULATIONS, IN HEALTHY ADULTS.PainEUCTR2013-001442-34-SEMcNeil AB